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Meningococcemia and meningococcal  meningitis in man appear to be infre- 
quent complications of the host-parasite relationship. Ordinarily, exposure to a 
strain of Neisseria mertingitidis  results in carriage of the organism in the naso- 
pharynx for weeks or months (1--4), producing either a mild pharyngitis or no 
symptoms at all (5, 6). Even during an epidemic,  the great majority of individ- 
uals exposed to the epidemic strain  of meningococcus become asymptomatic 
carriers rather than clinical cases with systemic disease (7). Viewed in this light, 
the occurrence of meningococcal disease is related more to the unique suscepti- 
bility of the individual host than to the innate virulence of the infecting or- 
ganism. 
Several epidemiol0gical  findings suggest that individuals who are susceptible 
to systemic meningococcal disease lack humoral  antibodies to meningococci. 
First, except for outbreaks among military recruits (8, 9) and other dosed popu- 
lations (10), meningococcal meningitis is a disease of infancy and early childhood 
(11, 12). This is true both in epidemic and interepidemic periods. Susceptibility 
to many so-called "diseases of childhood," bacterial and viral, has been shown 
to be associated with deficient levels of circulating antibodies to the infecting 
microbe (13). Second, the cyclical occurrence of epidemic meningococcal  disease 
in the United States at approximately 10 yr intervals (14) suggests that the dis- 
ease depends for its expression  on the presence of an immunologically virgin 
population. Third, meningococcemia seems to confer permanent immunity to 
future attacks of systemic meningococcal  disease,  although this is difficult to 
test statistically (10, 15). Convalescent sera from such cases have elevated levels 
of precipitating, agglutinating, complement-fixing,  opsonizing, bactericidal, and 
mouse-protective antibodies to the infecting meningococcus (16-18). 
The absence of a suitable animal model for the experimental study of men- 
ingococcemia  and meningococcal  meningitis has impeded the evaluation of the 
host-parasite relationship.  Antibodies to meningococcl  have been found to be 
present normaUy in blood from mouse, rat, guinea pig, rabbit, rhesus monkey, 
chimpanzee,  horse, and ox (19).1 It is possible that these antibodies are responsi- 
1 Goldschneider, I. Unpublished observations. 
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ble,  at  least in  part,  for  the  insensitivity of such  animals to meningococcal 
disease.  Similarly, antimeningococcal antibodies have  been  found  in  normal 
human  blood  (19-22).  These  observations, together with  the epidemiological 
findings presented above, suggest that httmoral antibodies may be important in 
preventing systemic meningococcal disease in man. 
Such an idea is not new. Kolmer et al. (23) showed that many normal human 
sera contain opsonic antibodies to meningococci isolated from cases of meningi- 
tis, and postulated that such antibodies might be protective. Heist et al. (24) 
found that blood from more than 95 % of normal men was bactericidal to menin- 
gococcal strains  obtained from  asymptomatic carriers. They postulated that 
most  cases  of meningitis  occur  among  those  few  individuals who  lack  bac- 
tericidal activity. Dr. Heist, whose own blood was nonreactive against meningo- 
cocci, died with meningococcal meningitis. While these early experiments were 
suggestive of a  protective role of circulating antibody against meningococcal 
disease, definitive evidence was lacking. The presentation of such evidence is 
the subject of this paper. 
Methods 
Ba¢leriological Techniques.-- 
Boxteria: Strains of Neisseria meningitldls  were obtained from  the collection of the De- 
partment of Bacteriology,  Walter Reed Army Institute of Research,  and from surveys con- 
ducted at several military installations, as indicated in the text. Specimens from blood and 
cerebrospinal fluid were plated on "chocolate" agar (Muener-Hinton  base [25], Difco Labora- 
tories, Detroit, Mich.), and those from nasopharynx on "chocolate" agar containing 6  /zg 
lincomycin  hydrochloride monohydrate  (Upjohn  Co.,  Kalamazoo,  Mich.)  and  25  units 
polymyxin B sulfate (Charles Pfizer & Co., New York) per milliliter (26). The plates were 
incubated for 16 to 24 hr at 37°C in the presence of moisture and COt (candle jar). Bacterial 
isolates were subcultured once on chocolate agar, without antibiotics, and identified as menin- 
gococci by serogrouping and fermentation of carbohydrates. The strains were preserved by 
lyophillzation,  and by freezing in a preserving  solution at  --70"C.  The preserving medium 
(27) consisted of 5% (w/v) bovine serum albumin (Calbiochem, Los Angdes, Calif.) and 5% 
(w/v)  monosodium  glutamate  (Sigma  Chemical  Co.,  St.  Louis,  Mo.)  in  distilled  water. 
Renewal  of the working  (frozen) stock was  made from  the lyophile collection.  Thus,  all 
meuingococcal strains used in the present experiments  were within two passages of original 
isolation. 
Serogrouping: The slide agglutination technique  (28) was employed for routine serogroup- 
ing of meningococci. Commercially obtained typing sera (Difco) were used to identify group 
A, B, and C organisms;  and rabbit antisera prepared in this laboratory against prototype 
organisms were used to type group Boshard (Bo), 135, and 29-Eur (29), and group X and Z 
(30). Serogroups Bo and Y  (30) were considered  to be identical (29). Meningococci which 
agglutinated spontaneously in saline,  which  were agglutinated by antisera to several sero- 
groups, or which were not agglutinated by any serum in the panel were called "nontypable" 
(NT). 
Carbohydrate fermentation: The bacterial isolates were tested for carbohydrate fermentation 
by a replicate plating method using a modified Lidwell phage applicator (31). Each strain was 
tested against dextrose,  maltose,  sucrose, and lactose.  Only bacteria which had typical co- 
louial morphology and fermented dextrose and maltose, or dextrose alone in the case of some 
sulfonamide-resistant  organisms  (32), were classified as N. meningitMis. GOLDSCHNEIDER~ GOTSCHLICH~ AND  ARTENSTELN  1309 
Preparation of bacterial suspensions: Bacteria were cultured on "chocolate" agar (Mueller- 
Hinton base, Difco lot No. 496202)  for 16 hr at 37°C in the presence of moisture and COs 
(candle jar). The organisms were subcultured for 5 hr on fresh chocolate agar and suspended 
in Dulbecco's (33)  phosphate-buffered  saline  (PBS)  pH 7.2  (Grand  Island  Biological  Co. 
Grand Island, New York). The concentration was adjusted to an optical density of 0.20  at 
TABLE I 
Sources o~ Children's Sera 
Group No.  Location 
Beth Israel  Hosp.,  Boston (Dr. 
Ronald Gold) 
Univ.  of  Miami,  Florida  (Dr. 
Bernard Fogel) 
Georgetown Univ., Washington, 
D. C. (Dr. Joseph Bellanti) 
Walter Reed Gen. Hosp., Wash- 
ington, D. C. (Dr. Win. Stew- 
art) 
Hosp. for Sick Children, Wash- 
ington,  D.  C.  (Dr.  Joseph 
Bellanti) 
Junior Village, Washington,  D. 
C.  (Dr.  Albert Kapikian) 
Div. Biol.  Standards, N. I. H., 
Bethesda,  Md.  (Dr. Paul 
Parkman) 
Age range 
Newborn 
Newbom---6 
months 
6months-2yr 
6  months-12  yr 
6months-12 yr 
6months-12 yr 
Donors 
Clinical  history 
Normal 
Normal 
Recurrent  upper 
respiratory  in- 
fections 
Normal 
Chronic  noninfec- 
tious  illnesses 
Normal 
7 months-12 yr  Normal 
No. 
serif 
11 
4~ 
45 
48 
79 
37 
Total...  282 
650 m# (16 X  125 mm Pyrex screw cap tube, Meteor Glass Co., Vineland, N. J.) in a spec- 
trophotometer  (Coleman Jr., model 6A). This corresponded  to a  colony count  of  approxi- 
mately 109 bacteria/ml. Appropriate dilutions were made in PBS. It was found that the total 
particle count, as measured in a hemocytometer, approximated  (-4-10%)  the viability count 
(colony count). 
Ssra.--Human blood was collected by venipuncture, atlowed to clot for 60 rain at room 
temperature,  and refrigerated at 4°C for 3 hr.  After centrifugation (1500 g for 10 rain)  the 
sera were placed in sterile 5 or 9 ml screw cap vials and stored at  --70°C. Sera were not re- 
frozen more than three times. C'H~0 hemolytic units (34) were determined on all sera defrosted 
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Children: Table I  shows the sources of sera from children. None of the children were re- 
ceiving antibiotics, gamma globulin, or immunosuppressant drugs. 
Adults: Serum was obtained from army recruits (ages 19-26 yr) during their 1st wk of basic 
training at Fort Dix, N. J., 1966-1968. Blood was drawn prior to the routine post-induction 
immunizations. 
Gamma  Globulln.--Lyophilized,  pooled  human gamma  globulin  (Cohn  fraction II,  Lot 
No. 2191) was obtained from E. R.  Squibb, Inc., New Brunswick, N. J. The gamma globu- 
lin was dissolved in PBS at a concentration of 10% (w/v) and centrifuged at 105,000 g (Spinco 
ultracentrifuge, model L) for 5 hr. 2~ae upper two-thirds of the supernate was retained, stored 
at 4°C, and used within 24 hr of preparation. 
Complement.--The source of complement was normal human serum (P. M.) which lacked 
bactericidal activity to  the strains of 3?.  meningitidis  used in this study.  The serum was 
divided into aliquots, stored at  --70°C, defrosted immediately prior to use and not refrozen. 
The donor was cultured repeatedly to ascertain that he did not become a carrier of meningo- 
cocci during the study. 
In all instances in which exogenous complement was not added to the bactericidal system 
C'Hs0 units/ml were determined by the method of Hook and Muschel (34). Only sera having 
140 or more C'Hs0 unlts/ml were considered in tabulating results. Amboceptor-coated sheep 
red blood calls were kindly provided by Mr. Earl Fife, Department of Serology, Waiter Reed 
Army Institute of Research. 
Antibody Assays.-- 
1.  Serum bactericidal reaction: The serum bactericidal test was performed in a  Microtiter 
system  (35)  using disposable U-well trays (Linbro Chemical Co., New Haven, Conn.), and 
25 and 50 #1 droppers and 25 and 50 ~1 diluters (Cooke Engineering Co., Alexandria, Va.). 
Plastic materials were sterilized by exposure to ethylene oxide (Anprolene, C. R. Bard, Inc.) 
for 16 hr. The diluters were flamed and allowed to cool prior to use. 
The reaction mixture had a total volume of 0.2 ml and consisted of one part diluted serum 
(or gamma globulin), one part PBS, one part complement (or PBS), and one part bacterial 
suspension  (approximately  104  bacteria/ml),  added  in  that  order.  Dulbecco's  phosphate- 
buffered saline (10  -3 ~  Ca  ++, 5  X  10  -4 M Mg  ++) was the diluent. Complement and heat- 
inactivated serum controls (56°C for 30 min) were included in each experiment. 
The tray was sealed with sterile (UV irradiation) transparent tape  (Cooke Engineering 
Co.), forcefully inverted to mix the reactants, and incubated at 37°C for 30 rain. After remov- 
ing the seal, the Microtiter tray was placed on edge and supported at an angle of approxi- 
mately 75  °  to  horizontal. Fluid from each well was  allowed to flow into a  glass capillary 
(Fisher Scientific Co., Pittsburgh, Pa.,  No.  12-141),  and a  drop was deposited on Mueller- 
Hinton agar which had been partially dehydrated by storage at room temperature for 4 to 8 
days.  Rapid  absorption of fluid by the agar terminated any residual bactericidal activity 
and also prevented dispersion of dividing bacteria. The capillaries delivered approximately 
0.02 ml per drop. In the absence of bactericidal activity such a drop contained approximately 
50 colony-forming units. The inoculated plates were incubated at 37°C for 18 to 24 hr and 
colony counts performed. 
a.  Interpretation  of bactericidal t,st:  Replicate  colony counts in several hundred  experi- 
ments showed the error in the system to be 4-20%. For this reason, only colony counts which 
were less than 50% of control levels were considered indicative of bactericidal activity. The 
50% level of killing was also chosen to maximize the sensitivity of the bactericidal assay. 
The 30 rain incubation period for the bactericidal reaction was selected for three reasons. 
First, sequential colony counts showed that the serum bactericidal activity against meningo- 
cocci was completed by 30 rain (usually by 15 min). Second, menlugococci placed in lag phase 
by suspending in PBS at room temperature did not divide in the complement or heated-serum 
controls during the 30 min incubation period, but did so after 60 rain. Third, viability counts GOLDSCHNEIDER, GOTSCHLICH~ AND ARTENSTEIN  1311 
of menlngococci  in PBS (or high serum dilutions) remained constant for 60 rain, but spon- 
taneously decreased  thereafter. 
Agglutination  of bacteria did not present a problem in the interpretation of colony counts 
after exposure of meningocoeei to serum. In low titer sera (bactericidal activity in dilutions 
less than 1:32) there was no significant agglutination. Such sera, when decomplemented by 
heating at 5CC for 30 rain, did not produce any depression in colony counts compared to 
complement or PBS controls. However, antibodies were apparently unaffected by the heat 
inactivation as evidenced by restoration of bactericidal activity after addition of complement, 
and by continued binding of specific IgG, IgM, and IgA antibodies to meningococci as deter- 
mined by indirect immunofluorescence (~/de Snfra). Agglutination  d/d occur ha some high titer 
sera, but was of no practical consequence in the interpretation of bactericidal activity. With 
few  exceptions, there was an abrupt transition between serum dilutions producing 100% 
killing and those showing 0% killing. 
Consistent results in the serum bactericidal system were obtained ff there was strict ad- 
herence to the procedures outlined. However, deviation in age of the bacterial culture (less 
than 4 hr or more than 6 hr), use of a different lot number of Mueller-I-Iinton  agar, or repeated 
passage of the meulngococcal  strain in vitro atteeted the reproducibility of the system, (i.e., 
increased or decreased  sensitivity of the meningococcal strain to the lethal action of antibody 
and complement). For this reason, comparable experiments were done at one time, or if this 
was not possible,  representative specimens were included as controls in subsequent experi- 
ments. 
2. Immuno#uores¢~e:  Indirect immunofluorescence was done using standard techniques 
(36). The antigens were 5 hr cultures of menJngococci, washed once with distilled water, sus- 
pended in distilled water at a concentration of 2 X  10  s bacterla/ml, and dried onto slides at 
37°C. Human sera were used in a standard dilution of 1:2 or titrated by serial 2-fold dilu- 
tions. Fluorescein-conjugated rabbit antisera to heavy chains of human IgG, IgM, or IgA 
globulins were used in a  1:20 dilution (Behringwerke,  Marburg-Lahn, Germany; distributed 
by Hoechst Pharmaceutical Co., Kansas City Mo.). Phosphate-buffered saline, pH 7.2 was 
the diluent throughout. 
The antigen was incubated at room temperature with human serum for 20 rain, washed in 
three changes of PBS (5 rain each), reinenbated for 20 rain in fluorescein-conjugated rabbit 
antiserum, rewashed, and mounted in buffered  glycerin (Difco).  Specimens were ~amined 
in a  Zeiss  Standard Universal microscope  (Carl Zeiss,  Inc., Oberkochen, West  Germany), 
equipped with a  100 X  apochromatic oil immersion objective with iris diaphragm, 8 X  eye- 
piece and 1.25 X  Optovar magnifying attachment. The ultraviolet light source was a 200 w 
mercury vapor arc lamp. A BG 12 excitation filter and a combination  of barrier filters Nos. 53 
and 44 were used. 
The sensitivities of the bactericidal and immunofluorescence (anti-IgG) assays for the de- 
tection of antimeningococcal antibodies in human sera were similar (=h one 2-fold serum dilu- 
tion). 
RESULTS 
Age-Related  Immunity---Fig.  1  shows  the  relationship between  serum bac- 
tericidal activity against N. meningiticlis and the incidence of systemic meningo- 
coccal disease in the general population, newborn to 26 yr of age. Three strains 
of meningococci, A1 (serogroup A), Bll  (serogroup B) and Cll  (serogroup C) 
from cases of meningitis were chosen as prototypes. These are the serogroups 
responsible for over 90 %  of cases of meningococcal meningitis (37). Age-specific 
morbidity rates for meningococcal infections in the United States in 1965 and 1312  IM%fUIqITy TO ~/ENINGOCOCCUS.  I 
1966 were obtained from the National Communicable Disease Center, Atlanta, 
Ga.  ~ Attack rates were calculated using estimated population  bases  for the 
various age groups (38). In addition, a survey of the age distribution of 72 cases 
of meningococcal meningitis admitted to Los Angeles Children's Hospital (1944- 
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FIG.  1.  Age-related incidence of meningococcal  disease  in the United States and preva- 
lence of  serum bactericidal activity against  three  pathogenic strains of  N.  meningitidis. 
&,  .&, number of eases/100,000  age-specific population, 1965; A  A, number of cases/ 
100,000 age-specific population, 1966; -~,  age distribution of 72 cases admitted to Los 
Angeles  Children's Hospital  1944-1953  (adapted  from Smith [39]);  •  O,  per cent of 
sera in each age group having a  bactericidal titer of 1:4 or greater against meningococcal 
strains A1, BI1, and Cll. Sera from 282 children (at least 20 in each age group) and 567 
army recruits (ages 19 to 26 yr) were tested in the presence of exogenous complement. Each 
point in the figure  represents the incidence of disease  or prevalence of bactericidal activity 
among subjects in the age range encompassed  by it and the previous point (e.g.,  2.5% of 
children 6-12 months of age had serum bactericidal activity against meningococeal strain A1). 
1953)  (39)  was  included  to provide more detailed data  on  the incidence of 
meningococcal disease during the first 2 yr of life. Inasmuch as two epidemics 
of meningococcal meningitis occurred between 1944 and 1953 (14), it is reasona- 
ble to assume that many of the cases among these children were caused by sero- 
group A (40). Cases occurring in 1965 and 1966 were due in the main to meningo- 
coccal serogroups B and C  (40). 
2 Courtesy of Ida Sherman, Acting Chief, Statistics Section,  Epidemiology Program. GOLDSCHNEIDER~  GOTSCHLICH, AND  ART~--NSTEIN  1313 
The data in Fig. 1 show that meningococcal disease is uncommon in the 1st 
month of life, but that significant numbers of cases begin to appear during the 
2nd and 3rd months. The peak incidence of meningococcal meningitis occurs 
between 6 months and 2 yr of age, after which there is progressive decrease in 
attack rate. A second, smaller peak occurs in the young adult population. This 
is due almost entirely to cases of meningococcal disease among military recruits 
(42--44). After age 25, the attack rate per year fluctuates between 0.3 and 0.5/ 
100,000 population. 
The per cent of individuals having bactericidal activity in their serum against 
the prototype strains of N. meningitidis is inversely proportional to the in- 
cidence of meningococcal meningitis during the first 12 yrs of llfe. Results in 
Fig. 1 show that sere from more than 50 % of newborn infants have bactericidal 
titers of at least 1:4 against one or more of the meningococcal test strains. The 
prevalence of bactericidal activity decreases rapidly after birth and reaches its 
lowest level between 6 months and 24 months of age. From 24 months to 12 yrs 
of age, there is an essentially linear increase in per cent of sera having bacteri- 
cidal activity. By ages 19-26 yr, serum from approximately 67 % of incoming 
military recruits has bactericidal activity against the serogroup A meningococ- 
cus, 86 % against serogroup B, and 76 % against serogroup C. These figures are 
only slightly higher than those for serum from newborn infants. 
Serum Bactericidal Activity and Susceptibility to Systemic Meningococcal Dis- 
ease.--It seems reasonable to hypothesize, on the basis of data presented in 
Fig. 1, that susceptibility to meningococcal meningitis is related to a deficiency 
of humoral antibodies as measured by the serum bactericidal test (45, 46). In 
order to test this hypothesis, a prospective study was started among incoming 
recruits at the U.S. Army base, Fort Dix, N. J. Recruits were bled during the 
1st wk of basic training and the sera stored at -  70°C in anticipation of the oc- 
currence of meningococcemia or meningococcal meningitis among some of the 
men during the 8 wk training period. This serum is referred to as base line serum, 
as opposed to acute phase serum collected on the day of onset of clinical disease 
(often after parenteral administration of antibiotics). In all, 14,744 recruits were 
bled between 1 December 1967 and 31 March 1968, among which 60 cases of 
systemic meningococcal disease occurred. In every instance in which the or- 
ganism was isolated, it belonged to serogroup C. At the peak of the meningitis 
outbreak in February, the attack rate reached 0.5 per 100 recruits per 4 wk 
training--a rate approximately 300 times greater than that current in the civil- 
ian population of the United States (47). 
Base line serum from each case was tested for bactericidal activity against the 
strain of meningococcus isolated from his blood or cerebrospinal fluid (homolog- 
ous strain). 10 control base line sera, selected at random from men in the same 
training platoon as the case, were also tested against the meningococcal isolate. 
There were 46 instances in the prospective study in which both base line serum 1314  ~UNITY  TO  MEN1NGOCOCCUS.  I 
and the infecting meningococcal strain were available for study. In addition, 
base line sera from five group C cases of meningitis which occurred at Fort Dix, 
winter 1966 and spring 1967, and sera from three cases occurring in April 1968 
were included,  along with appropriate control  sera. Results of this study are 
summarized in Table II. 
It is clear from the data that base line sera from cases of systemic meningo- 
coccal disease lack bactericidal  activity to the homologous disease-producing 
strain of meningococcus. Only 5.6 % of base line sera from cases had bactericidal 
TABLE IT 
Meningococcocidal Activity of Base Line Sera* from Prospective Cases of Meningococcal Disease 
Meningococci 
Homologous strains:[:. 
Other pathogenic strains 
AI (serogroup A) 
BI1 (serogroup B) 
Cll (serogroup C) 
Strain  from  carrier  (G-2-81) 
(Serogroup Y) 
Bactericidal tlter 1:4 or greater 
Base  line sera  Base  llne sera 
from cases  from contro]s 
No.  ~ositlw/to~l  (%) 
3/s4  (5.6) 
4/23  (17.4) 
3/23  (13.0) 
2/23  (8.7) 
21/23  (91.3) 
444/54o  (82.2) 
166/230  (72.2) 
179/230  (77.8) 
154/23o (67.0) 
221/230  (96.1) 
Statistical 
e <  o.oo1§ 
e <  0.00111 
e <  0.00111 
e <  0.00111 
e  >  0.75011 
* Obtained from recruits in 1st wk of basic training at Fort Dix, N. J., 1967-1968. 
:~ Isolated from patients whose  base line sera were tested. Base line serum from each case 
of meningococcal  disease was tested against his own meniagococcal  strain. Base line sera from 
10 controls were tested against each strain (total 540 control sera)o 
§ Calculated using Fishers exact test for 2 X 2 tables (63). 
I1 Calculated by the method of x  ~ (63). 
activity in dilutions of 1:4 compared to 82.2 % of control sera. Further, results 
in Table II indicate that base line sera from cases are relatively deficient in their 
ability to kill disease-producing strains of meningococci in general. Thus,  the 
proportion of base line sera from cases able to kill prototype strains A1, Bll, 
and Cll was significantly lower than that of controls. The mean titer of control 
sera having bactericidal  activity against  meningococcal  strain  A1  was  1:16 
(range 1:4 to 1:128). However, when tested against meningococcal strain G-2- 
81  (serogroup ¥)  isolated from the nasopharynx of an asymptomatic carrier, 
base line sera from cases killed as frequently as did control sera. 
Immunological Deficit in Sera from Susceptible Host Population.--There  are 
several possible explanations for the inability of base line sera from cases of 
meningococcal meningitis to kill their own and other disease-producing strains GOLDSCHNEIDER,  GOTSCHLICH, AND ARTENSTEIN  1315 
of meningococci. The sera could be deficient in antibody to the respective strains 
of meningococci by lack of previous (or recent) contact with relevant antigens; 
or as a result of a more general defect in immunoglobulin production such as 
hypogamnaaglobulinemia or dysgammaglobulinemia.  There could be inhibitors 
of the bactericidal reaction,  abnormalities in complement  components,  or ab- 
sence of ancillary factors necessary for the bactericidal  reaction.  The following 
experiments were performed to distinguish which of these defects is the one most 
commonly observed. 
Base line sera from cases of menlngococcal meningitis are deficient in anti- 
bodies to pathogenic strains of menlngococci. This was shown by an experiment 
in which  antimeningococcal  antibodies (IgG)  to prototype strain Cll  (sero- 
group C) were measured by indirect immunofluorescence. Antibodies to strain 
Cll were not found among 20 of 23 base line sera from cases of group C men- 
ingitis. 21 of these sera lacked bactericidal activity to Cll (Table II). However, 
23 bactericidal sera from controls each had detectable antimeningococcal anti- 
bodies to strain Cll (immunofluorescent titer 1:2 or greater). 
Three cases in Table H had bactericidal activity  in their base line sera to their 
own menlngococcal isolates. The cause of this lethal activity is not known. No 
immunoglobulins  from classes G, M, or A were found by immunofluorescence 
to be directed against the homologous menlngococcal strains. In contrast, of 10 
control sera having bactericidal activity to these meningococcal strains, all had 
antimeningococcal antibodies (10, IgG; 6, IgM; and 3, IgA). 
Base line sera from 23 cases had an average of 169.5 C'Hs0 unlts/ml (range 
162.2 to 186.5 units) control sera  176.8 C'Hs0 units/ml (range  157.9 to 189.4 
units), both within the established normal range for the procedure  (34). 
Sera from susceptible  individuals do not appear to lack factors other than 
antibody which are necessary for bactericidal activity against meningococci, 
nor do such sera contain inhibitors of the bactericidal reaction (e.g., blocking 
antibodies,  anticomplementary substances).  As seen in Table II, 21 of 23 base 
line  sera from cases of meningitis were bactericidal  to menlngococcal  strain 
G-2-81. Further, such  sera were fully able to restore  the ability of purified 
gamma globulin to kill pathogenic strains of menlngococci. Table III records the 
results of an experiment in which a standard amount of base line serum was 
added in lieu of complement to serially diluted pooled human gamma globtilin 
(Cohn fraction H; 10 mg/ml). In seven of eight instances, the bactericidal titers 
against the prototype C  strain were essentially the same whether base line 
serum from cases or the standard complement source was used to supply the 
effector mechanism for bactericidal activity. In the one exception  (No. 7123), 
the complement titer was below normal. 
The data indicate that individuals who are susceptible to systemic meningo- 
coccal disease lack humoral antibody to the offending strain of menlngococcus 
(as well as to other case strains). However,  the results in Table IV show that 1316  DdMUNITY TO  MENINGOCOCCUS. I 
such individuals are capable of responding immunologically during the course 
of infection. Bactericidal titers against homologous strains of meningococci were 
determined in convalescent sera obtained from 11 cases of meningitis which oc- 
curred at Fort Dix, N. J.,  in  1968.  The sera were drawn at least  1 wk after 
cessation of antibiotic therapy (usually potassium penicillin). In each instance, 
there was a  marked increase in bactericidal activity, reciprocal titers ranging 
from 256 to 2048.  Base line serum from these cases had titers of less than 1:4 
(Table II). 
TABLE III 
Reconstitution of Bactericidal Activity of Human Gamma Globulin by Sera* from Prospective 
Cases of Meningococcal Disease 
Sera 
Description  Code No. 
Base line sers from prospective cases 
of meningococcal  disease 
2,651 
6,884 
7,123 
8,860 
9,587 
10,325 
10,662 
12,059 
Reciprocal bactericidal titert 
Serum (1:4) + 
Serum  gamma globulin§ 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
256 
128 
32 
256 
128 
128 
128 
128 
Complement  (P.  M.) ...............................  <4  128 
* Base llne sera from recruits in 1st wk of training at Fort Dix, N. J., 1967-1968. 
:~ Tested against meningococcal  strain Cll (serogroup C). 
§ Cohn fraction II (10% w/v) diluted serially in twofold steps. Serum added to final 
dilution of 1:4. Gamma  globulin had no bactericidal activity by ite~If. 
The rise in bactericidal activity in convalescent serum is reflected by the ap- 
pearance of IgG, IgM, and IgA antibodies to the patient's own strain of men- 
ingococcus, lmmunoglobulin titers were measured by indirect immunofluores- 
cence in acute and convalescent sera from four cases of meningitis. As shown in 
Table V, there was a marked,  specific  rise in level of the three classes of im- 
munoglobulin within 2 wk of onset of disease.  It is of interest that there were 
no detectable antibodies to the homologous meningococcal strains in acute sera 
from these four cases. 
Fate of Susceptible Host Population.--While it is evident that base line sera 
from cases of meningococcal disease  lack  bactericidal  antibody to  the  causa- 
tive organism, it is also true that serum from as many as 35 % of young adult 
males is unable to kill disease-producing strains of meningococci. Why, then, 
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epidemic conditions such as existed at Fort Dix in the winter of 1967-68?  Three 
possibilities exist, none of which are mutually exclusive: (a) The majority of 
susceptibles are not exposed to meningococci of proved pathogenicity; (b) fac- 
tors other than circulating antibody predominate in defense against systemic 
meningococcal disease; (c) subclinical cases of meningococcemia occur. 
An intensive study of three basic training companies at Fort Dix, N. J., in 
1968 provides information on these points. The object was to determine the 
number of men in each training group who acquired pathogenic strains of men- 
TABLE IV 
Bactericidal Activity of Convalescent '3era flora  Cases of Meningococ~al Dise~e* 
Code No. 
A-612 
A-616 
A-635 
A-637 
A-640 
A-645 
A-651 
A-656 
A-668 
A-670 
A-677 
Scra 
Date obtained 
12 April 
4 April 
23 April 
20 Ap~ 
28 March 
5 April 
9 April 
4 April 
12 April 
17 April 
6 April 
Onset of disease 
11 March 
9 March 
25 March 
22 March 
28 February 
8 March 
12 March 
25 February 
12 March 
18 March 
13 March 
Reciprocal bactericidal 
titer$ 
1024 
512 
512 
1024 
512 
2048 
1024 
1024 
1024 
512 
256 
* Fort Dix, N. J.,  1968.  All cases caused by group C meningococci. 
Serum from each patient was tested  against his own meningococcal isolate.  Exogenous 
complement was  added.  Titers  of base  line sera to  the homologous  strains  were less  than 
1:4 (Table H). 
ingococci against which they lacked serum bactericidal activity. Summarized 
data from this study are presented in Table VI. 
492 men from the three companies were bled and had nasopharyngeal cul- 
tures taken during the 1st, 3rd, 5th, and 7th wk of basic training. Five proved 
cases of meningococcal meningitis, all due to sulionamide-resistant, serogroup C 
organisms, occurred during the study period; three in E-5-3 Company (March), 
one in E-5-3  Company (April), and one in E-2-3  Company (April). The two 
E-5-3  companies were completely independent training companies. One addi- 
tional case of meningitis in E-2-3  Company (April) was suspected to be men- 
ingococcal in origin, but was not confirmed bacteriologically. 
Bactericidal activity of the 1st wk serum from each recruit was tested against 
the meningococcal strain(s) isolated from the case(s) within his training com- 
pany. Results in Table VI show that 54 of 492 (11%) recruits had bactericidal 
titers less than 1:4 against the case strains. This group is defined as the suscepti- 1318  IMMUNITY  TO  MENINGOCOCCUS.  I 
TABLE  V 
Antimeningococcal Antibodies of Immunoglobulln  Classes G, M, and A*  in Sera from 
Recruits with Meningococcal Di~ease~ 
Pa~ent 
J.H. 
C° C. 
C° S. 
S.C. 
Sera 
Code ~o. 
A-199 
A-200 
A-321 
A-322 
A-420 
A-421 
A-428 
A-430 
Date obtained 
u/~9/6611 
11/25/66 
1/16/6711 
1/23/67 
3/16/6711 
3/24/67 
4/21/6711 
4/28/67 
Reciprocal immtmofluorescence  titer~ 
igo 
<2 
128 
<2 
128 
<2 
64 
<2 
512 
rgM 
<2 
64 
<2 
128 
<2 
64 
<2 
512 
r~A 
<2 
32 
<2 
64 
<2 
32 
<2 
128 
* Determined by indirect immunofluorescence. 
Fort Dix, N. J. All cases caused by group C meningocoeci. 
§ Sera tested against the patient's own meningococcal  isolate. 
[I Date of onset of disease. 
TABLE VI 
Incidence of Meningococcal Disease among Susceptible Recruits al Fort Dix, N. J.,  1968 
Training  Company 
E-5-3 (March) 
E-5-3 (April) 
E-2-3 (April) 
Total.. 
Sera lacking 
bactericidal  ac- 
tivity  to  case 
strains* 
No. negative/ 
total 
30/195 
13/185 
11/112 
54/492 
Meningococcal  isolates§ 
No.  No. 
positive/total  sezo~roup 
16 
3 
5 
24 
Susceptible populations 
Bactericidal activity 
to acquired C, 
strain 
No. posltive/total 
8/16 
1/3 
2/s 
28/30 
8/23 
8/12 
44/54  I1/24 
* All cases caused by sulfa-resistant, group C memngococci. 
Incidence  of men- 
insococcal disease 
No. cases/No, ezpose,  d 
susce~es (%) 
3/8  (37.5) 
112 (so.o) 
1/311(33.3) 
s/13  (38.s) 
:~ Individuals lacking serum bactericidal activity to disease-producing strains of meningo- 
cocci prevalent in their basic training companies. 
§ From carriers and cases. 
I[ An additional case of meningitis occurred, but the etiological agent was not identified. 
ble host population, i.e., the population at highest risk to systemic disease from 
meningococcal strains of proven pathogenicity within the immediate environ- 
ment. 
44 of the 54 presumed susceptible individuals became carriers of a  meningo- GOLDSCHNEIDER~ GOTSCHLICH, AND  ARTENSTEIN  1319 
coccus after the 1st wk of training. Of these, 24 (44.4 % of the original 54) ac- 
quired a sulfonamide-resistant,  group C meningococcus. However, serum from 
11 of the men had bactericidal activity against the acquired  group C strain, 
indicating that their organisms were different from the case strains. Thus, of the 
original 54 susceptibles, only 13 were exposed to meningococci compatible with 
the prevalent pathogenic strains and to which they had no bactericidal activity. 
The five (and possibly six) cases of meningitis  occurred among this group--an 
incidence of 38.5 %. 
DISCUSSION 
Susceptibility to meningococcal disease in man is related to a selective de- 
ficiency of antibody to the offending organism. This conclusion derives from two 
experiments  in which susceptibility to infection and bactericidal  activity of 
serum were compared. In the first experiment, it was found that the age-specific 
incidence  of meningococcal  disease  in the general  population of the United 
States is inversely proportional to the prevalence  of antimeningococcal  bac- 
tericidal antibodies in the serum. In the second experiment,  a study was initi- 
ated among military recruits to measure the bactericidal  activity of sera from 
prospective cases of meningococcal disease. The results show that base line sera 
from cases lack antibodies to the homologous meningococcal strains. Such serum 
is not only deficient in antibodies to the patient's own strain, hut to heterolog- 
ous disease-producing strains as well--suggesting a lack of immunity to patho- 
genic meningococci in general. The lack of antimeningococcal antibodies in base 
line sera from cases was confirmed by indirect immunofluorescence. 
3 of 54 sera from prospective  cases of meningitis d/d kHll homologous and 
heterologous  strains of meningococci. However,  neither gamma G, M, nor A 
antimeningococcal  antibodies were present as judged by jmmunofluorescence. 
The cause of the bactericidal activity in these three sera is thus unknown. 
The deficiency in sera  from susceptible  hosts is confined to antibodies to 
meningococci. Hemolytic complement  levels are normal, and addition of exo- 
genous complement does not increase bactericidal activity: The sera are fully 
able to effect bactericidal reactions against meningococcal case strains when 
reconstituted with purified human gamma globulin (Cohn fraction II). Further- 
more, unsupplemented base line sera could kill a group Y strain of meningococ- 
cus which was isolated from an asymptomatic carrier. 
While sera from susceptible hosts lack antibody to the offending meningococ- 
cus, such individuals are capable of initiating an immune response to mening- 
ococcal antigens. Thus, convalescent  sera from cases of meningitis have mar- 
kedly increased contents of IgG, IgM, and IgA antibodies to their own mening- 
ococcal strain. This increase in antibody titer is accompanied by a sharp rise in 
bactericidal activity. That the deficiency of antimeningococcal  immunoglobu- 
lins in sera of susceptibles is not part of a generalized immunological deficiency 
syndrome is shown by normal total immunoglobulin concentrations in acute 1320  TA4-MUNITY  TO M-ENINGOCOCCUS. I 
sera from cases (48) and by the absence of a clinical history of unusual suscep- 
tibility to other infectious diseases. 
Two previous  studies  have  suggested  that  the  prevalence  of antimeningococcM 
antibodies  in blood  from  normal  individuals  increases  as  a  function  of age  of the 
donor. Matsunami and Kolmer (19)  titrated the bactericidal activity of whole blood 
from 26 children,  ages 6 months to 10 yr, and from normal adults. They concluded 
that the blood from children was "somewhat less" meningococcocidal than that from 
adults. Silverthorne and Fraser (49) also compared bactericidal activity of blood from 
children and adults. 23 of 33 blood samples from adults were positive against a patho- 
genic strain of meningococcus, compared to 0 of 11 samples from children less than 2 
yr old. Both of these studies suggested that children several months to 2 yr of age 
lack serum bactericidal antibodies to pathogenic meningococci, whereas most adults 
have such antibodies.  This is consonant with  the findings of the present  study.  In 
addition, these earlier experiments suggested that young children also lack opsonizing 
antibodies to meningococci. 
There is considerable precedent in the literature  of infectious diseases  for relating 
susceptibility  to  systemic disease  to  absence  of humoral  antibodies.  Many  of  the 
so-called "diseases  of childhood" have a  reciprocal relationship  between  the curves 
formed by age-related  incidence of infection and presence  of antibacterial  or anti- 
toxic antibodies in serum (13). Perhaps the most striking example is that of meningitis 
caused  by  Haemophilus  influenzae.  Fothergill  and  Wright  (50)  found  an  inverse 
relationship between incidence of H. influenzae meningitis and  bactericidal power of 
blood almost identical with that shown for N. meningitldis in the present study. Not 
only did the percentage of individuals with sera capable of killing the organism in- 
crease progressively after age 3 yr, but the mean bactericidal potency of their  sera 
also increased. Other diseases  of childhood in which the development of immunity has 
been shown to be directly related to a  progressive increase in prevalence of specific 
humoral antibodies with age are diphtheria (51), scarlet fever (52), poliomyelitis (53), 
and mumps  (54). 
The strongest evidence that antimeningococeal antibodies in "normal"  serum are 
protective against systemic meningococcal disease is the observation that meningococ- 
cal meningitis is unusual in the neonatal period  (39,  55,  56)  but increases with the 
onset  of physiological hypogammaglobulinemia (57).  Analogy with  the  diseases  of 
childhood cited above suggests that this is due to the  transient protective effect of 
passively  transferred  maternal  antibody  (58).  The  successful  use  of hyperimmune 
animal serum in the treatment of systemic meningococcal disease  (59)  supports the 
thesis that antimeningococcal antibodies in serum of normal human beings are pro- 
tective.  Bactericidal  and opsonic antibodies  (60)  were present  in these  therapeutic 
sera; such antibodies have been described in normal human sera (19-22). 
Work  in  nonimmunized  animals  also  suggests  a  protective  role  for  "natural" 
humoral  antibodies  against  meningococci.  Matsunami  and  Kolmer  (19),  using  a 
single  strain of meningococcus, showed that the relative abilities of several types of 
laboratory animals to survive challenges with graded doses of bacteria correlated with 
the bactericidal titers of whole blood against the organisms. Recently, Evans et al.3 
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demonstrated a positive correlation between the abilities of numerous group B strains 
of meningococci  to survive in normal rat serum in vitro and their abilities to cause 
disease in the rat in vivo. 
It is important to emphasize that results of the present experiments  are not 
interpreted to indicate that serum bactericidal  activity per se is the protective 
factor in natural immunity against meningococcal disease. The serum bacter- 
icidal test was used only as a sensitive indicator of specific antibodies to men- 
ingococci. Such antibodies may have other functions in addition to bactericidal 
activity (e.g., opsonization);  or other, nonbactericidal,  antibodies  may play a 
role. Indeed, there is no evidence that humoral antibodies are the sole, or even 
the major host defense mechanism. Phagocytic cells of the reticuloendothelial 
system, for example, are undoubtedly of importance in confining and eliminat- 
ing the meningococcus, and local factors in the nasopharynx may also contrib- 
ute. Nevertheless,  it does seem clear from the present experiments  that a de- 
ficiency of circulating antimeningococcal  antibodies is firmly associated with 
the establishment of menlngococcemia. Epidemiological  observations  support 
this conclusion. Thus, while people with humoral antibodies against meningo- 
cocci frequently  become carriers of the organisms# they rarely become cases (6). 
On the other hand, people who become cases rarely harbor the meningococcus 
in the nasopharynx more than a few days prior to onset of systemic disease (6, 
61). This is presumably because,  in susceptible  individuals,  invasion of the 
deeper tissues and blood occurs before the carrier state can be established. The 
relation between the factors that control the carrier state and humoral protec- 
tive antibodies is not known. However,  a later report in this series (62) shows 
that  systemic immunization with  meningococcal  products  can  affect local 
defenses to the meningococcus. 
It has been established  that meningococcal meningitis is a disease which is 
spread by asymptomatic carriers (1, 2). Numerous studies have suggested that 
the incidence  of clinical disease is related to the introduction and spread of 
pathogenic strains of meningococci in the population (1, 7). Our studies sug- 
gested that, even during an epidemic, meningococcal disease occurs in only a 
fraction of the predicted susceptibles. An attempt was made, therefore, to deter- 
mine the fate of the individuals comprising the susceptible population during 
an epidemic of group C meningitis at Fort Dix, N.J. 
In a group of 492 basic recruits in three training companies, 54 were found to 
lack serum bactericidal activity against the prevalent disease-producing strains. 
44 of this presumed susceptible  group acquired a meningococcus during the 8 
wk of training, but in only 13 instances were the organisms compatible with 
the case strains. Of the 13 exposed susceptibles, 5 developed systemic meningo- 
coccal diseasc  an incidence of 38.5 % of susceptibles, but only 1% of the total 
population. These findings indicate that the majority of susceptible individuals 1322  r~rlTNITy  TO  ~NINGOCOCCUS.  I 
escaped clinical infection because they were not exposed to the prevalent strains 
of pathogenic meningococci. 
It is not surprising that all the potentially susceptible individuals did not 
become cases upon exposure to the pathogenic strains of meningococci.  The 
fact that base line sera from cases of meningitis have bactericidal titers of less 
than 1:4 does not mean that all people with titers below this level are suscep- 
tible to infection, although  many obviously are. Furthermore,  other factors, 
such as intensity of exposure to pathogenic organisms,  may be more instru- 
mental in determining the incidence of diseases than exposure per se. Finally, it 
is possible that in some instances subclinical  meningococcemia occurred and 
was not detected. 
SUMMARY 
Susceptibility to  systemic meningococcal  disease is  related  to  a  selective 
deficiency of humoral antibodies to pathogenic strains of meningococci.  In a 
study of the age-specific incidence  of meningococcal meningitis in the United 
States, it was found that the proportion of individuals with serum bactericidal 
activity to meningococci  of serogroups A, B, and C was reciprocally related to 
the incidence of disease. The prevalence of bactericidal activity was highest at 
birth  and among adults,  and lowest in infants between 6 and  24 months  of 
age. 
Sera from 51 of 54 prospective cases of meningococcal disease among military 
recruits were deficient in antibodies to homologous and heterologous strains of 
pathogenic meningococci as determined  by serum bactericidal  activity and 
indirect immunofluorescence.  Such sera, however, could support the bactericidal 
activity of purified human gamma globulin (Cohn fraction II), and such in- 
dividuals could respond immunologically to infection with meningococci.  The 
implication is that susceptible persons are deficient in antimeningococcal anti- 
bodies because they have not received significant  exposure to meningococcal 
antigens in the past. 
The fate of individuals who lack bactericidal antibodies to pathogenic men- 
ingococci  was determined  during  an outbreak of group  C meningitis  among 
miHtaxy recruits. The incidence  of disease was found to be primarily associated 
with the incidence of exposure of susceptibles to the pathogenic strains.  Whereas 
81.5 % of the presumed susceptibles acquired a meningococcal strain, only 24.1% 
acquired an organism similar to the prevalent disease-producing strains. Of the 
exposed susceptibles, 38.5 % developed systemic meningococcal  disease. 
We wish to thank those physicians listed in Table I  for their help in obtaining sera from 
children. SP5 K. O'Brien and SP5 J. Funk assisted in collecting the sera from recruits. Colonel 
T. H. Lamson and Major W. Morgan helped coordinate the collection of sera and bacterio- 
logical specimens at Fort Dix, N. jr. Mr.  C. Harkins supervised the diagnostic bacteriology. 
We are indebted to SP5 J. Wilczek for invaluable technical assistancc in performance of the 
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